Iranian journal of allergy, asthma, and immunology最新文献

筛选
英文 中文
The Effectiveness of Probiotics in Treating Food and Cow's Milk Allergies among Pediatric Age Group: A Meta-analysis of Randomized Controlled Trials. 益生菌治疗儿童食品和牛奶过敏的有效性:一项随机对照试验的meta分析。
IF 1.5 4区 医学
Iranian journal of allergy, asthma, and immunology Pub Date : 2023-04-30 DOI: 10.18502/ijaai.v22i2.12674
Hua Feng, Yongning Wu
{"title":"The Effectiveness of Probiotics in Treating Food and Cow's Milk Allergies among Pediatric Age Group: A Meta-analysis of Randomized Controlled Trials.","authors":"Hua Feng, Yongning Wu","doi":"10.18502/ijaai.v22i2.12674","DOIUrl":"https://doi.org/10.18502/ijaai.v22i2.12674","url":null,"abstract":"The global prevalence of allergies is on the rise. Food allergies are of special concern among children under 5 years of age, leading to morbidity and mortality. Though the standard management is avoidance, probiotics are being used widely to prevent and treat food allergies. We aimed to determine the effect of probiotics as a therapeutic option for controlling food and cow's milk allergy among children under 5 years of age. A systematic search of electronic medical literature databases was conducted. We included all eligible randomized controlled trials available from inception until May 2021. The primary outcome of interest was the relief of allergic symptoms, while the secondary outcome was the induction of tolerance. Two investigators undertook the literature search, screening, data extraction, and quality appraisal independently. Data analysis and synthesis were performed using STATA 14 software. Subgroup analysis was performed for the duration of use and follow-up, and the age category of children included in the outcome were done. Twenty trials involving 4043 pediatric patients with food allergies were included in the review. Subgroup analysis also revealed that probiotics were effective in treating food allergies across the various subgroups included in the model. Around 15 trials reported our primary outcome, relief of symptoms, as a binary variable, which was pooled to obtain a risk ratio of 0.86 (95% confidence interval [CI], 0.77-0.95), with very low heterogeneity (I2 7.7%). Six trials were included for the secondary outcome of interest, which gave an imprecise pooled estimate of 1.29 (95% CI, 0.98-1.70) with significant heterogeneity (I2 7). Thus, we conclude that probiotics can serve as a vital therapeutic option in tackling food allergies among children less than 5 years of age. Further larger studies exploring the effectiveness of individual strains and their safety pattern are essential.","PeriodicalId":14560,"journal":{"name":"Iranian journal of allergy, asthma, and immunology","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2023-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9947633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Investigating the Safety and Efficacy of the Synthetic Drug Herbix on Immune Responses Involved in the Treatment of a Mouse Model of Herpes Simplex Virus. 研究合成药物Herbix治疗小鼠单纯疱疹病毒模型免疫反应的安全性和有效性。
IF 1.5 4区 医学
Iranian journal of allergy, asthma, and immunology Pub Date : 2023-02-20 DOI: 10.18502/ijaai.v22i1.12008
Mohammad Ali Khodadoust, Gholam Reza Keramatian, Najmeh Kaffash Farkhad, Jalil Tavakol-Afshari
{"title":"Investigating the Safety and Efficacy of the Synthetic Drug Herbix on Immune Responses Involved in the Treatment of a Mouse Model of Herpes Simplex Virus.","authors":"Mohammad Ali Khodadoust,&nbsp;Gholam Reza Keramatian,&nbsp;Najmeh Kaffash Farkhad,&nbsp;Jalil Tavakol-Afshari","doi":"10.18502/ijaai.v22i1.12008","DOIUrl":"https://doi.org/10.18502/ijaai.v22i1.12008","url":null,"abstract":"<p><p>Herpes simplex virus-1 (HSV-1) infections can cause significant harm to individuals, including blindness, congenital defects, genital herpes, and even cancer, with no definitive cure .so, finding new treatment strategies is crucial. In this study, 25 male BALB/c mice were used to conduct a mouse model of herpes by subcutaneously injecting an HSV-1 suspension (100 µL of 1×  PFU/mL). The mice were divided into 5 groups with groups 1 to 3 designated as intervention groups, and groups 4 and 5 serving as positive and negative control groups, respectively. After 2 days of virus inoculation, the mice were treated with different concentrations of Herbix (100, 200, and 300 mg/mL) via subcutaneous injection. Mice Blood samples (0.5 to 1 mL) were taken from the mice before and after the experiments, and after three-week follow-up period, the mice were sacrificed and the spleens were removed for lymphocyte analysis. we found that administration of Herbix at a dose of 300 mg/mL showed the greatest efficacy, characterized by a delay in skin lesion formation, an increment in survival rate and lymphocyte proliferation, upregulation of the gene expression of interferon alpha (IFN-α) and tumor necrosis factor alpha (TNF-α), and an increase in the polarization of cytotoxic and helper T lymphocytes compared to the control group. These results suggest that Herbix at a dose of 300 mg/mL is effective in treating murine herpes and stimulating immune responses, making it a potential candidate for further investigation as an antiherpetic drug.</p>","PeriodicalId":14560,"journal":{"name":"Iranian journal of allergy, asthma, and immunology","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2023-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9233372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New Presentation of CD27 Deficiency; Coronary Ectasia and COVID-19. CD27缺乏的新表现冠状动脉扩张与COVID-19
IF 1.5 4区 医学
Iranian journal of allergy, asthma, and immunology Pub Date : 2023-02-20 DOI: 10.18502/ijaai.v22i1.12013
Zahra Golchehre, Samin Sharafian, Nader Momtazmanesh, Zahra Chavoshzadeh, Abdollah Karimi, Hassan Abolhassani, Maryam Kazemi Aghdam, Koroush Vahidshahi, Seyedehatefeh Hashemimoghaddam, Farid Kosari, Zahra Khafafpour, Bibi Shahin Shamsian, Mohammad Keramatipour
{"title":"New Presentation of CD27 Deficiency; Coronary Ectasia and COVID-19.","authors":"Zahra Golchehre,&nbsp;Samin Sharafian,&nbsp;Nader Momtazmanesh,&nbsp;Zahra Chavoshzadeh,&nbsp;Abdollah Karimi,&nbsp;Hassan Abolhassani,&nbsp;Maryam Kazemi Aghdam,&nbsp;Koroush Vahidshahi,&nbsp;Seyedehatefeh Hashemimoghaddam,&nbsp;Farid Kosari,&nbsp;Zahra Khafafpour,&nbsp;Bibi Shahin Shamsian,&nbsp;Mohammad Keramatipour","doi":"10.18502/ijaai.v22i1.12013","DOIUrl":"https://doi.org/10.18502/ijaai.v22i1.12013","url":null,"abstract":"<p><p>CD27 is a costimulatory receptor involved in the maturation of the innate and adaptive immunity. CD27, through interaction with CD70, plays a role in the control of Epstein-Barr virus (EBV) infection. CD27 deficiency leads to an immune dysregulation disease characterized by EBV susceptibility. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might put patients with primary immunodeficiency at risk for adverse outcomes. Chromogenic in situ hybridization (CISH) study was performed to detect EBV in the lymphoma tissue. Genetic analysis of the patient was done with Whole Exome Sequencing and detected variant was confirmed with PCR-Sanger sequencing. Here we report a 20-month-old boy with CD27 deficiency who developed lymphoma and coronary artery ectasia and had been infected with SARS-CoV-2. Clinical and laboratory findings were incompatible with atypical Kawasaki syndrome or multisystem inflammatory syndrome in children (MIS-C). As CD27 deficiency is a rare immune defect, publishing clinical data about the identified patient(s) can shed light on our knowledge about the related phenotype and the spectrum of clinical manifestations associated with CD27 deficiency. Thus, our findings expanded the spectrum of manifestations beyond EBV infection, highlighting this unusual cardiac sequela that could be related to EBV infection, lymphoma, or an underlying disease.</p>","PeriodicalId":14560,"journal":{"name":"Iranian journal of allergy, asthma, and immunology","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2023-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9239911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Immunosuppressive Effects of Two Probiotics, Lactobacillus paracasei DSM 13434 and Lactobacillus plantarum DSM 15312, on CD4+ T Cells of Multiple Sclerosis Patients. 副干酪乳杆菌DSM 13434和植物乳杆菌DSM 15312对多发性硬化症患者CD4+ T细胞的免疫抑制作用
IF 1.5 4区 医学
Iranian journal of allergy, asthma, and immunology Pub Date : 2023-02-20 DOI: 10.18502/ijaai.v22i1.12004
Khadijeh Chakamian, Behrouz Robat-Jazi, Abdorreza Naser Moghadasi, Fatemeh Mansouri, Masoumeh Nodehi, Elahe Motevaseli, Maryam Izad, Saeed Yekaninejad, Mahdieh Shirzad, Kiana Bidad, Mona Oraei, Bita Ansaripour, Ali Akbar Saboor-Yaraghi
{"title":"Immunosuppressive Effects of Two Probiotics, Lactobacillus paracasei DSM 13434 and Lactobacillus plantarum DSM 15312, on CD4+ T Cells of Multiple Sclerosis Patients.","authors":"Khadijeh Chakamian,&nbsp;Behrouz Robat-Jazi,&nbsp;Abdorreza Naser Moghadasi,&nbsp;Fatemeh Mansouri,&nbsp;Masoumeh Nodehi,&nbsp;Elahe Motevaseli,&nbsp;Maryam Izad,&nbsp;Saeed Yekaninejad,&nbsp;Mahdieh Shirzad,&nbsp;Kiana Bidad,&nbsp;Mona Oraei,&nbsp;Bita Ansaripour,&nbsp;Ali Akbar Saboor-Yaraghi","doi":"10.18502/ijaai.v22i1.12004","DOIUrl":"https://doi.org/10.18502/ijaai.v22i1.12004","url":null,"abstract":"<p><p>T cells play an important role in the development and progression of multiple sclerosis (MS), an autoimmune disease of the central nervous system. In the present study, the immunomodulatory impacts of two Lactobacillus strains, L paracasei DSM 13434 and L plantarum DSM 15312, on the frequency and cytokine production of CD4+ T cells in MS patients were explored. Thirty MS patients were enrolled in this study. The CD4+ T cells were isolated, cultured, and exposed to the media containing cell-free supernatants of L plantarum (group1), L paracasei (group 2), the mixture group of cell-free supernatants of both probiotics (group 3), and vehicle (control) group (group 4). The frequencies of T helper (Th) 1, Th17, Th2, and T regulatory type 1 (Tr1) cells and mean fluorescent intensity (MFI) of the associated cytokines were assessed using flow cytometry. The levels of interleukin 17 (IL-17), transforming growth factor β (TGF-β), and interferon-gamma (IFN-γ) cytokines in supernatants of all groups were measured by enzyme-linked immunosorbent assay. The percentage of Th1 cells and the MFI of IFN-γ in Th1 cells (CD4+ IFN-γ+) in all three probiotic treatment groups were significantly decreased compared to the control group. However, no significant changes were observed in the proportion and MFI of Th2, Th17, and Tr1 cells. A significant decrease was observed in IL-17 secretion in the supernatant of cultured CD4+ T cells in all three treatment groups in comparison with control. The levels of TGF-β and IFN-γ were not significantly different among any of the study groups.  Collectively, cell-free supernatants of the lactobacilli showed an in vitro anti-inflammatory effect. However, further studies are needed to prove the real effects of probiotics on MS.</p>","PeriodicalId":14560,"journal":{"name":"Iranian journal of allergy, asthma, and immunology","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2023-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9233369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Itraconazole Improved Bronchial Wall Thickness in Severe Persistent Asthma: A Double-blind Placebo-controlled Randomized Clinical Trial. 伊曲康唑改善严重持续性哮喘患者支气管壁厚度:一项双盲安慰剂对照随机临床试验。
IF 1.5 4区 医学
Iranian journal of allergy, asthma, and immunology Pub Date : 2023-02-20 DOI: 10.18502/ijaai.v22i1.12000
Farnaz Aligolighasemabadi, Majid Mirsadraee, Mohammadamin Sadeghdoust, Shadi Ghaffari, Mohammad Sarafraz Yazdi, Saeed Naghibi, Amirhossein Hashemi Attar
{"title":"Itraconazole Improved Bronchial Wall Thickness in Severe Persistent Asthma: A Double-blind Placebo-controlled Randomized Clinical Trial.","authors":"Farnaz Aligolighasemabadi,&nbsp;Majid Mirsadraee,&nbsp;Mohammadamin Sadeghdoust,&nbsp;Shadi Ghaffari,&nbsp;Mohammad Sarafraz Yazdi,&nbsp;Saeed Naghibi,&nbsp;Amirhossein Hashemi Attar","doi":"10.18502/ijaai.v22i1.12000","DOIUrl":"https://doi.org/10.18502/ijaai.v22i1.12000","url":null,"abstract":"<p><p>The purpose of this study was to evaluate the effect of 8 months of treatment with itraconazole on airway wall thickness in patients with severe persistent asthma. It was a double-blind, randomized, placebo-controlled clinical trial (IRCT20091111002695N9). Seventy-five subjects with severe persistent asthma received itraconazole (100 mg), prednisolone (5 mg), or placebo twice a day for eight months in three treatment groups (n=25 in each group). The primary objective was to improve the right upper lobe apical segmental bronchus (RB1) wall thickness percentage measured by high-resolution computed tomography scan of the lungs. Other morphometric measurements of RB1, asthma control test (ACT) score, presence of wheezing, dyspnea severity, rate of asthma exacerbation, fractional exhaled nitric oxide (FeNO), and expiratory volume in 1 second (FEV1) were set as the secondary outcomes. Wall thickness percentage reduced significantly from 46% to 43.7% from pre- to post-treatment in the itraconazole-treated subjects. Similarly, lumen area and radius increased significantly in both the prednisolone and itraconazole groups. Itraconazole led to a significant improvement in wheezing, dyspnea severity, FEV1, ACT score, and FeNO. Although prednisolone was also effective in improving pulmonary function tests and ACT scores, it was associated with significantly more side effects than itraconazole. Long-term treatment with itraconazole resulted in a significant reduction in bronchial wall thickness and improvements in clinical findings and pulmonary function tests. Thus, itraconazole could be a helpful add-on treatment option for severe persistent asthma patients to achieve better disease control.</p>","PeriodicalId":14560,"journal":{"name":"Iranian journal of allergy, asthma, and immunology","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2023-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9239912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Changes in PD-1- and CTLA-4-bearing blood lymphocytes in ICU COVID-19 patients treated with Favipiravir/Kaletra or Dexamethasone/Remdesivir: a pilot study. Favipiravir/Kaletra或地塞米松/Remdesivir治疗ICU COVID-19患者PD-1-和ctla -4血淋巴细胞的变化:一项初步研究
IF 1.5 4区 医学
Iranian journal of allergy, asthma, and immunology Pub Date : 2023-02-20 DOI: 10.18502/ijaai.v22i1.12012
Esmaeil Mortaz, Hamidreza Jamaati, Neda K Dezfuli, Hakime Sheikhzade, Seyed MohammadReza Hashemian, Neda Dalil Roofchayee, Frazaneh Dastan, Payam Tabarsi, Gert Folkerts, Johan Garssen, Sharon Mumby, Ian M Adcock
{"title":"Changes in PD-1- and CTLA-4-bearing blood lymphocytes in ICU COVID-19 patients treated with Favipiravir/Kaletra or Dexamethasone/Remdesivir: a pilot study.","authors":"Esmaeil Mortaz,&nbsp;Hamidreza Jamaati,&nbsp;Neda K Dezfuli,&nbsp;Hakime Sheikhzade,&nbsp;Seyed MohammadReza Hashemian,&nbsp;Neda Dalil Roofchayee,&nbsp;Frazaneh Dastan,&nbsp;Payam Tabarsi,&nbsp;Gert Folkerts,&nbsp;Johan Garssen,&nbsp;Sharon Mumby,&nbsp;Ian M Adcock","doi":"10.18502/ijaai.v22i1.12012","DOIUrl":"https://doi.org/10.18502/ijaai.v22i1.12012","url":null,"abstract":"<p><p>COVID-19, caused by SARS-CoV-2, requires new approaches to control the disease. Programmed cell death protein (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) play important roles in T-cell exhaustion in severe COVID-19. This study evaluated the frequency of whole blood lymphocytes expressing PD-1 and CTLA-4 in COVID-19 patients upon admission to the intensive care unit (ICU) (i.e., severe) or infection ward (i.e., moderate) and after 7 days of antiviral therapy. COVID-19 patients were treated with either favipiravir or Kaletra (FK group, 11 severe and 11 moderate) or dexamethasone plus remdesivir (DR group, 7 severe and 10 moderate) for 7 days in a pilot study. Eight healthy control subjects were also enrolled. The frequency of PD-1+ and CTLA-4+ lymphocytes in whole blood was evaluated by flow cytometry. Patients on DR therapy had shorter hospital stays than those on FK therapy. The frequency of PD-1+ lymphocytes in the FK group at baseline differed between COVID-19 patients and healthy controls, while the frequency of both PD-1+ and CTLA-4+ cells increased significantly 7 days of FK therapy. The response was similar in both moderate and severe patients. In contrast, the frequency of PD-1+ and CTLA-4+ lymphocytes varied significantly between patients and healthy controls before DR treatment. DR therapy enhanced PD-1+ but not the CTLA-4+ frequency of these cells after 7 days. We show that the frequency of PD-1 and CTAL-4-bearing lymphocytes during hospitalization was increased in Iranian ICU COVID-19 patients who received FK treatment, but that the frequency of CTLA-4+ cells was higher at baseline and did not increase in patients who received DR. The effectiveness of DR treatment may reflect differences in T-cell activation or exhaustion status, particularly in CTLA-4-expressing cells.</p>","PeriodicalId":14560,"journal":{"name":"Iranian journal of allergy, asthma, and immunology","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2023-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9239395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
MicroRNA-122 Is More Effective than Rapamycin in Inhibition of Epithelial-mesenchymal Transition and mTOR Signaling Pathway in Triple Negative Breast Cancer. MicroRNA-122 在抑制三阴性乳腺癌上皮-间质转化和 mTOR 信号通路方面比雷帕霉素更有效
IF 1.5 4区 医学
Iranian journal of allergy, asthma, and immunology Pub Date : 2023-02-20 DOI: 10.18502/ijaai.v22i1.12006
Majdedin Ghalavand, Ruhollah Dorostkar, Hojat Borna, Samira Mohammadi-Yeganeh, Seyed Mahmood Hashemi
{"title":"MicroRNA-122 Is More Effective than Rapamycin in Inhibition of Epithelial-mesenchymal Transition and mTOR Signaling Pathway in Triple Negative Breast Cancer.","authors":"Majdedin Ghalavand, Ruhollah Dorostkar, Hojat Borna, Samira Mohammadi-Yeganeh, Seyed Mahmood Hashemi","doi":"10.18502/ijaai.v22i1.12006","DOIUrl":"10.18502/ijaai.v22i1.12006","url":null,"abstract":"<p><p>The fundamental mechanism responsible for the aggressiveness of metastatic cancers such as triple-negative breast cancer (TNBC) is the epithelial-mesenchymal transition (EMT). In cancer microenvironments, the Phosphoinositide 3-kinases (PI3K)-Akt- mammalian target of rapamycin (mTOR) signaling pathway plays a critical role in regulating the EMT mechanism. The current study focuses on the impacts of rapamycin, a newly retargeted chemotherapeutic agent against mTOR, and MicroRNA (miR)-122 on the aggressive behavior of TNBC.  The half-maximal inhibitory concentration (IC50) of rapamycin on 4T1 cells was determined using an MTT assay. Also, miR-122 was transiently transfected into 4T1 cells to study its effect on the pathway. Quantitative real-time polymerase chain reaction (qRT-PCR) was conducted to assess the expression level of central mTOR and EMT-related cascade genes. Moreover, cell mobility and migration were evaluated using scratch and migration assays, respectively. Both rapamycin and miR-122 significantly decreased the expression levels of PI3K, AKT, and mTOR, as well as ZeB1 and Snail genes. However, no significant change was observed in Twist gene expression. Furthermore, scratch and migration assays revealed that the migration of 4T1 cells was markedly reduced, especially following miR-122 induction. Our experimental findings and gene enrichment studies indicated that miR-122 mainly operates on multiple metabolic pathways, as well as EMT and mTOR, while rapamycin has restricted targets in cancer cells.  Consequently, miR-122 can be considered a potential cancer microRNA therapy option, which can be validated in the future in animal studies to demonstrate its efficacy in cancer control.</p>","PeriodicalId":14560,"journal":{"name":"Iranian journal of allergy, asthma, and immunology","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2023-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9233371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dysregulation of Immunity in Pulmonary Fibrosis is Associated with Increased Myeloid-specific Triggering Receptor-1 and Transforming Growth Factor-beta1 Expression. 肺纤维化中免疫失调与骨髓特异性触发受体-1和转化生长因子- β -1表达增加有关
IF 1.5 4区 医学
Iranian journal of allergy, asthma, and immunology Pub Date : 2023-02-20 DOI: 10.18502/ijaai.v22i1.12002
Shima Rasouli, Jalal Heshmatnia, Nariman Mosaffa, Majid Marjani, Esmaeil Mortaz
{"title":"Dysregulation of Immunity in Pulmonary Fibrosis is Associated with Increased Myeloid-specific Triggering Receptor-1 and Transforming Growth Factor-beta1 Expression.","authors":"Shima Rasouli,&nbsp;Jalal Heshmatnia,&nbsp;Nariman Mosaffa,&nbsp;Majid Marjani,&nbsp;Esmaeil Mortaz","doi":"10.18502/ijaai.v22i1.12002","DOIUrl":"https://doi.org/10.18502/ijaai.v22i1.12002","url":null,"abstract":"<p><p>Fibrosing pneumonia (FP) is classified into usual interstitial pneumonia (UIP) and nonspecific interstitial pneumonia (NSIP), each having its own etiology and prognosis. Both types of FP are progressive and chronic conditions with distinct etiologies. Cytokines and inflammatory mediators play critical roles in the pathogenesis of FP. Among them, the role of transforming growth factor beta-1 (TGF-β1) and modulators triggering fibrosis are not well understood. In this study, the expression of triggering receptor expressed on myeloid cells-1 (TREM-1) as a stimulator for the production of TGF-β1 and also CD4+CD25+Foxp3+ regulatory cells were investigted in FP patients. Sixteen UIP, 14 NSIP and 4 pulmonary fibrosis following Mycobacterium tuberculosis (TB) infection patients, were compared with 12 healthy controls. The frequency of blood CD14+TGF-β1+ and CD14+TREM1+-gated monocytes and CD4+CD25+Foxp3+ regulatory T cells (Treg), as well as the plasma levels of TGF-β1 and IL‑10 were measured. Fibrosis patients compared to healthy controls had a greater frequency of CD14+TGF-β1+ [15.9 (0.2-88.2) vs. 0.6 (0.2-11.0)] and CD14+TREM1+ [21.1 (2.3-91.2) vs. 10.3 (3.1-28.6)]-gated monocytes, and CD4+CD25+Foxp3+ [1.2 (0.3-3.6) vs. 0.2 (0.1-0.4)]-gated lymphocytes. Plasma TGF-β1 were also significantly increased in patients with fibrosis compared to healthy controls [9316.2 (±5554.4) vs. 3787.5 (±2255.6)]. These results confirm the importance of TGF-β1 and TREM1 in pulmonary fibrosis. It seems that this reciprocal cycle in healthy people is modulated by the production of IL‑10 by Treg cells, thus limiting fibrosis, as observed in patients following TB infection. Further investigations are recommended to evaluate possible immunomodulatory mechanisms defects in pulmonary fibrosis.</p>","PeriodicalId":14560,"journal":{"name":"Iranian journal of allergy, asthma, and immunology","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2023-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9239906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Investigating the Relationship between the Levels of IL18, RANKL Gene Expression, MicroRNA-146a and Inflammatory Factors with the Severity of COVID-19. 研究 IL18、RANKL 基因表达、MicroRNA-146a 和炎症因子水平与 COVID-19 严重程度之间的关系。
IF 1.5 4区 医学
Iranian journal of allergy, asthma, and immunology Pub Date : 2023-02-20 DOI: 10.18502/ijaai.v22i1.12009
Karmand Hamad Khdhir, Shahriar Alipour, Shiva Gholizadeh-Ghaleh Aziz, Seyed Hesamaddin Banihashemi
{"title":"Investigating the Relationship between the Levels of IL18, RANKL Gene Expression, MicroRNA-146a and Inflammatory Factors with the Severity of COVID-19.","authors":"Karmand Hamad Khdhir, Shahriar Alipour, Shiva Gholizadeh-Ghaleh Aziz, Seyed Hesamaddin Banihashemi","doi":"10.18502/ijaai.v22i1.12009","DOIUrl":"10.18502/ijaai.v22i1.12009","url":null,"abstract":"<p><p>COVID-19 can induce lung inflammation, and inflammatory factors play an essential role in its pathogenesis. This inflammation can be controlled to a great extent by microRNAs(miRs). This study evaluated miR-146a-5p expression levels in the serum of patients with COVID-19 and their association with the expression of interleukin (IL)-18 and receptor activator of nuclear factor kappa-Β ligand (RANKL) genes, and lung damage. patients with COVID-19 were divided into two groups: mild and severe phases. The severe phase is defined as having a positive polymerase chain reaction (PCR) for SARS-CoV2, and acute pulmonary symptoms. The subjects' demographic, clinical, and paraclinical characteristics were collected according to a pre-prepared checklist. Total RNA was isolated from all samples using the Trizol kit to assess gene expression. The extracted product was then evaluated for the expression of miR-146a and the target genes (i.e., IL-18 and RANKL) using real-time PCR. The miR-146a gene's mean expression in mild and severe patients was 0.73 and 1.89, respectively, and this difference was statistically significant between the two groups. Also, the mean Expression of the IL-18 gene, 1.37±0.38 in the mild and 2.83±0.58 in the severe groups of the disease, demonstrated a significant difference between the two groups. In contrast, the expression levels of the RANKL gene did not show a significant difference between the two groups. Therefore, it may be hypothesized that altered levels of miR-146a may contribute to the severe COVID-19 that is more commonly observed in smokers, but further research is required.</p>","PeriodicalId":14560,"journal":{"name":"Iranian journal of allergy, asthma, and immunology","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2023-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9233370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
MicroRNA-124 Enhances T Cells Functions by Manipulating the Lactic Acid Metabolism of Tumor Cells. MicroRNA-124通过调控肿瘤细胞的乳酸代谢增强T细胞功能。
IF 1.5 4区 医学
Iranian journal of allergy, asthma, and immunology Pub Date : 2023-02-20 DOI: 10.18502/ijaai.v22i1.12007
Mohammad Khakpoor-Koosheh, Hosein Rostamian, Elham Masoumi, Leila Jafarzadeh, Keyvan Fallah-Mehrjardi, Mohammad Javad Tavassolifar, Farshid Noorbakhsh, Hamid Reza Mirzaei, Jamshid Hadjati, Nima Rezaei
{"title":"MicroRNA-124 Enhances T Cells Functions by Manipulating the Lactic Acid Metabolism of Tumor Cells.","authors":"Mohammad Khakpoor-Koosheh,&nbsp;Hosein Rostamian,&nbsp;Elham Masoumi,&nbsp;Leila Jafarzadeh,&nbsp;Keyvan Fallah-Mehrjardi,&nbsp;Mohammad Javad Tavassolifar,&nbsp;Farshid Noorbakhsh,&nbsp;Hamid Reza Mirzaei,&nbsp;Jamshid Hadjati,&nbsp;Nima Rezaei","doi":"10.18502/ijaai.v22i1.12007","DOIUrl":"https://doi.org/10.18502/ijaai.v22i1.12007","url":null,"abstract":"<p><p>High production of lactic acid is a common feature of various tumors. Lactic acid is an immunosuppressive molecule with crucial roles in tumor cells' immune escape, which could largely be attributed to its negative effects on the T cells present in the tumor microenvironment (TME). Strategies that decrease the glycolysis rate of tumor cells could enhance immunosurveillance and limit tumor growth. Pyruvate kinase M2 (PKM2) is a key enzyme in the glycolysis pathway, and it plays a vital role in lactic acid buildup in the TME. MicroRNA (miR)-124 has been shown to be able to decrease tumor cell lactic acid synthesis indirectly by reducing PKM2 levels. In this study, we first overexpressed miR-124 in the tumor cells and evaluated its effects on the PKM2 expression and lactic acid production of the tumor cells using quantitative real-time polymerase chain reaction (qRT-PCR) and spectrophotometry, respectively. Then, we cocultured miR-124-treated tumor cells with T cells to investigate the effects of miR-124 overexpression on T cell proliferation, cytokine production, and apoptosis. Our results demonstrated that miR-124 overexpression could significantly reduce the amount of lactic acid produced by tumor cells by manipulating their glucose metabolism, which led to the augmented proliferation and IFN-γ production of T cells. Moreover, it rescued T cells from lactic acid-induced apoptosis. Our data suggest that lactic acid is a hindering factor for T-cell-based immunotherapies; however, manipulating tumor cells' metabolism via miR-124 could be a promising way to improve antitumor responses of T cells.</p>","PeriodicalId":14560,"journal":{"name":"Iranian journal of allergy, asthma, and immunology","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2023-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9233373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信